These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 9368704)
1. Eosinophil chemotaxis induced by several biologically active substances and the effects of apafant on it in vitro. Nabe T; Yamamura H; Kohno S Arzneimittelforschung; 1997 Oct; 47(10):1112-6. PubMed ID: 9368704 [TBL] [Abstract][Full Text] [Related]
2. Effects of nedocromil sodium and WEB 2086 on chemoattractant-stimulated neutrophil migration through cellular and noncellular barriers. Carolan EJ; Casale TB Ann Allergy; 1992 Oct; 69(4):323-8. PubMed ID: 1329582 [TBL] [Abstract][Full Text] [Related]
3. Triple role of platelet-activating factor in eosinophil migration across monolayers of lung epithelial cells: eosinophil chemoattractant and priming agent and epithelial cell activator. Liu L; Zuurbier AE; Mul FP; Verhoeven AJ; Lutter R; Knol EF; Roos D J Immunol; 1998 Sep; 161(6):3064-70. PubMed ID: 9743372 [TBL] [Abstract][Full Text] [Related]
4. PAF-mediated platelet adhesion to endothelial cells induced by FMLP-stimulated leukocytes. Hirafuji M; Shinoda H J Lipid Mediat; 1991 Nov; 4(3):347-51. PubMed ID: 1662550 [TBL] [Abstract][Full Text] [Related]
5. The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils. Miyagawa H; Nabe M; Hopp RJ; Okada C; Bewtra AK; Townley G Agents Actions; 1992 Sep; 37(1-2):39-43. PubMed ID: 1456179 [TBL] [Abstract][Full Text] [Related]
6. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats. Akagi M; Nishioka E; Kanoh R; Tachibana M; Fukuishi N Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165 [TBL] [Abstract][Full Text] [Related]
7. Activity of a novel thienodiazepine derivative as a platelet-activating factor antagonist in guinea pig lungs. Effects on platelet-activating factor and allergen induced eosinophil accumulation. Tsunoda H; Sakuma Y; Shirato M; Obaishi H; Harada K; Yamada K; Shimomura N; Machida Y; Yamatsu I; Katayama K Arzneimittelforschung; 1991 Mar; 41(3):224-7. PubMed ID: 1867658 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation. Ring PC; Seldon PM; Barnes PJ; Giembycz MA Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515 [TBL] [Abstract][Full Text] [Related]
9. Effects of apafant on PAF-induced downregulation of beta-adrenoceptors in guinea pigs. Sugimoto Y; Nakayama Y; Kishida H; Hayakawa T; Fujiwara R; Kamei C Methods Find Exp Clin Pharmacol; 1997 Oct; 19(8):547-52. PubMed ID: 9442478 [TBL] [Abstract][Full Text] [Related]
10. Density heterogeneity of eosinophil leucocytes: induction of hypodense eosinophils by platelet-activating factor. Yukawa T; Kroegel C; Evans P; Fukuda T; Chung KF; Barnes PJ Immunology; 1989 Sep; 68(1):140-3. PubMed ID: 2807369 [TBL] [Abstract][Full Text] [Related]
11. Activation of guinea pig eosinophils by human recombinant IL-5. Selective priming to platelet-activating factor-acether and interference of its antagonists. Coëffier E; Joseph D; Vargaftig BB J Immunol; 1991 Oct; 147(8):2595-602. PubMed ID: 1655895 [TBL] [Abstract][Full Text] [Related]
12. The effect of the selective PAF antagonist WEB 2170 on PAF and antigen induced airway hyperresponsiveness and eosinophil infiltration. Seeds EA; Coyle AJ; Page CP J Lipid Mediat; 1991; 4(1):111-21. PubMed ID: 1893085 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of neutrophil and eosinophil chemotactic responses to PAF by the PAF-antagonists WEB-2086, L-652,731, and SRI-63441. Håkansson L; Venge P J Leukoc Biol; 1990 May; 47(5):449-56. PubMed ID: 2335754 [TBL] [Abstract][Full Text] [Related]
14. Priming of eosinophil recruitment in vivo by LPS pretreatment. Macari DM; Teixeira MM; Hellewell PG J Immunol; 1996 Aug; 157(4):1684-92. PubMed ID: 8759756 [TBL] [Abstract][Full Text] [Related]
15. Eosinophil infiltration and enhancement of airway reactivity by leukocyte chemotactic factor, formyl-methionyl-leucyl-phenylalanine (fMLP), in guinea pigs. Amagai M; Ohashi Y; Makino S Arerugi; 1992 Nov; 41(11):1547-60. PubMed ID: 1492788 [TBL] [Abstract][Full Text] [Related]
16. Platelet-activating factor-induced human eosinophil transendothelial migration: evidence for a dynamic role of the endothelium. Casale TB; Erger RA; Little MM Am J Respir Cell Mol Biol; 1993 Jan; 8(1):77-82. PubMed ID: 8380250 [TBL] [Abstract][Full Text] [Related]
17. Formation of LTB4 by fMLP-stimulated alveolar macrophages accounts for eosinophil migration in vitro. Hidi R; Coëffier E; Vargaftig BB J Leukoc Biol; 1992 May; 51(5):425-31. PubMed ID: 1318347 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613 [TBL] [Abstract][Full Text] [Related]